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EGF = epidermal growth factor; EGFR = EGF receptor; FAK = focal adhesion kinase; GAP = GTPase activating factor; GDF = GDI-dissociation
factor; GDI = guanine nucleotide dissociation inhibitor; GDP = guanosine diphosphate; GEF = guanine nucleotide exchange factor; GTP = guano-
sine triphosphate; IBC = inflammatory breast cancer; IGF = insulin-like growth factor; IGFBP = IGF-binding protein; IGFBP-rP = IGFBP-related
protein; IGF-IR = IGF-I receptor; IR = insulin receptor; IRS = insulin receptor substrate; MAPK = mitogen activated protein kinase; PI3K = phos-
photidylinositol 3-kinase; ROCK = Rho kinase.
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Introduction
Inflammatory breast cancer (IBC) is a highly aggressive
form of locally advanced breast cancer that carries a
guarded prognosis due to its propensity to disseminate via
the dermal lymphatics and metastasize to distant organs
[1]. Tumor recurrence or outgrowth of occult metastases
are common in IBC and account for the lowest 5-year
disease-free survival rate of all breast cancers (<45%,
compared with an 86% 5-year disease-free survival rate
for all breast cancers) [1,2]. RhoC GTPase was found to
be preferentially overexpressed in IBC tumors versus
stage-matched, non-IBC tumors [3], and was found to be
a breast-specific oncogene that could impart motile and
invasive capabilities to breast epithelial cells akin to the
IBC phenotype [4]. The invasive and metastatic properties
of pancreatic adenocarcinoma and melanoma have also
been attributed to RhoC overexpression [5]. These exam-
ples of Rho protein expression and activation in aggres-
sive cancers illustrate the importance of these molecules
in understanding progression to a metastatic phenotype.
Because of their similarity to Ras, a great deal of excite-
ment has ensued since the discovery of the Rho GTPases
in the mid-1980s as potential key oncogenes involved in
cancer. Unlike Ras, no activating mutations have been
demonstrated for Rho. Instead, overexpression and/or
activation, in the absence of mutation, appears to be the
rule in human cancers [6]. The importance of Rho proteins
in conferring motile and invasive properties that contribute
to the metastatic phenotype is becoming increasingly
appreciated [4,7]. The Rho GTPases control all aspects of
cellular motility and invasion, including polarity, cytoskele-
tal organization, and transduction of signals from the extra-
cellular environment, particularly from growth factors
[4,7,8]. To be fully effective in achieving the invasive phe-
notype, the Rho proteins most likely need to complete a
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Abstract
A variety of phenotypic characteristics are required for a cancer cell to successfully complete the
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particularly in response to growth factors. Dysregulation of Rho activation through aberrant growth-
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full GTPase cycle and continue to cycle, alternating
between an inactive and active state [9–12]. Although one
Rho protein may predominate in cancer cell, a reciprocal
activation of different GTPases must occur during cycling
(e.g. RhoC is active while Rac1 is inactive and vice versa),
thus allowing cells to effectively reorganize the cytoskele-
ton and to form lamellipodia and filopodia. This is best
illustrated when constitutively active RhoA is introduced
into fibroblasts, leading to the formation of stable stress
fibers and a nonmotile cell [7]. The need for reciprocal
activation during cell motility is perhaps the reason why no
activating mutations, such as those identified for Ras, have
been found for Rho in human cancers.
Like Ras, Rho proteins are activated via extracellular
signals that cause binding and hydrolyses of GTP and
induction of downstream effector molecules, leading to a
cellular response [8]. Although 21 members of the Rho-
GTPase subfamily have been identified to date, the vast
majority of data exists for RhoA, Rac1, and Cdc42 [7]. As
suggested above, it is the activation state of these and
other Rho proteins, and not the level of expression, that
dictates the cellular effects. Therefore, attention is turning
to potential mechanisms of aberrant Rho activation, such
as alterations in the regulatory proteins or aberrant growth
factor stimulation.
As outlined in Fig. 1, growth-factor-stimulated activation of
Rho occurs through the interactions of several Rho regula-
tory proteins, such as the GTPase-activating proteins
(GAPs), guanine nucleotide dissocation inhibitors (GDIs),
GDI-dissociation factors (GDFs), and guanine nucleotide
exchange factors (GEFs) [12–15]. The entire cycle is bal-
anced by GDIs, which prevent guanosine diphosphate
(GDP) dissociation and sequester Rho in the cytoplasm.
The GDP-bound, inactive Rho is liberated from the GDI by
the GDF and is localized to the inner plasma membrane.
Activation of the GEFs by tyrosine kinase growth factor
receptors leads to exchange of GDP for guanosine triphos-
phate (GTP), thus activating Rho [14,15]. Simultaneously,
growth-factor-receptor-induced phosphorylation of p120
RasGAP leads to heterodimer binding and inactivation of
p190 RhoGAP, allowing the GTPase to remain active [13].
GTP binding produces a conformational change in Rho
leading to interaction with and activation of downstream
effector proteins, such as Rho kinase (ROCK) for RhoA
and RhoC, or p21 activated kinase (Pak) for Rac and
Cdc42 [16,17,18]. Binding affinities for the effector pro-
teins vary with the GTPases. For example, RhoC has a
greater binding affinity for ROCK than RhoA [16]. These
differences in binding may be key in producing an invasive
phenotype in cells preferentially expressing a GTPase such
as RhoC [16,17]. Through unknown mechanisms, the
RasGAP/RhoGAP heterodimer dissociates, and the now
active GAPs catalyze hydrolysis of remaining GTP to GDP,
inactivating Rho and closing the cycle [13].
Growth-factor-induced Rho activation and
cancer cell motility
Studies have suggested that dysregulation of the GTPase
cycle is due to altered expression of the key Rho regula-
tory proteins described above. The best examples of this
are the GEF proteins, which were originally identified as
oncogenes, and p190-A RhoGAP, which was first
described as a tumor suppressor gene [15,18,19].
Several other studies have focused on the role of growth
factor receptors and their ligands in the activation of Rho
GTPases and the induction of cancer cell motility. Onco-
genic versions of the IGF-I receptor (IGF-IR) or the Her
family of growth factor receptors activate RhoA, Rac1,
Cdc42, and possibly RhoC [20,21]. During cancer pro-
gression, early dysregulation of growth factor signaling,
such as EGFR amplification or Her2/neu expression, may
lead to a mitogenic effect required for tumor cell growth
and survival. However, later in the progression of the
cancer, these same signals may activate overexpressed
Rho GTPases, driving metastasis [22]. Therefore, overex-
pression of Rho by itself is not sufficient to achieve a
Figure 1
The GTPase cycle. RhoGDIs (1) sequester Rho GTPases in the
cytoplasm and prevent GDP dissociation until released by RhoGDFs
(2). The Rho protein attaches to the inner cytoplasmic membrane by
prenylation of the protein. When a protein tyrosine kinase growth factor
receptor (3), such as EGFR, is activated, p120 RasGAP is
phosphorylated and forms a heterodimer with p190 RhoGAP, leading
to inactivation of those proteins. The RhoGEF proteins (4) are also
phosphorylated, causing exchange of GDP for GTP (6) on the Rho
proteins, leading to Rho activation. Active, GTP-bound Rho proteins
activate downstream Rho effector proteins (7), which stimulate cellular
motility and invasion (8). RhoGAP (9) is released and activated,
catalyzing the hydrolysis of GTP to GDP (10) and inactivating the Rho
protein. EGFR = EGF receptor; GAP = GTPase activating factor; 
GDF = GDI-dissociation factor; GDI = guanine nucleotide dissociation
inhibitor; GDP = guanosine diphosphate ; GEF = guanine nucleotide
exchange factor; GTP = guanosine triphosphate.
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metastatic phenotype. However, when coupled with aber-
rant growth factor signaling, the active form of the GTPase
drives metastasis.
The insulin-like growth factors (IGFs)
The process of motility is similar for both normal migrating
cells and invasive or metastatic cancer cells, requiring
dynamic reorganization of the actin cytoskeleton in
response to external stimuli. Normal epithelial cells grow
and undergo lateral migration in tight sheets in which cells
are connected to one another by cell–cell adhesions (i.e.
cadherin–catenin complexes) and to the extracellular
matrix (ECM) by cell–matrix adhesions [23]. The ability of
an epithelial cell to migrate individually is a hallmark of
tumorigenic cells that requires cellular depolarization and
turnover of cell–ECM contact sites known as focal adhe-
sions [23,24]. Focal adhesions contain integrins,
cytoskeletal and signaling proteins such as α-actinin and
focal adhesion kinase (FAK). Focal adhesion turnover and
cellular motility is decreased in fibroblasts derived from
FAK–/– mice [23]. Reexpression of FAK leads to transient
inhibition of RhoA and RhoC activity, ROCK activation,
restoring focal adhesion turnover, and cell migration
[23,25], suggesting that completion of the GTPase cycle
by RhoA and RhoC is required for focal adhesion turnover
and cell motility. Loss of FAK activity results in constitutive
activation of Rho/ROCK and decreased migration.
The observations made in fibroblasts provide a framework
for studying growth factor induced motility in epithelial
derived cancers. Stimulation of IGF-IR overexpressing
MCF-7 breast cancer cells with IGF-I leads to actin fila-
ment disassembly, cellular depolarization, and the forma-
tion of fascin microspikes associated with lamellipodia
[24,26]. Signaling from IGF-IR to the actin cytoskelton
during depolarization and cell separation appears to be
mediated by the actin-binding protein α-actinin [27]. These
cellular changes involve the activation of the phosphotidyli-
nositol 3-kinase (PI3K) pathway and transient phosphotyro-
sine-phosphotase-mediated dephosphorylation of FAK,
and two other focal adhesion-associated molecules, p130-
Crk-associated substrate (Cas) and paxillin [26]. However,
increased activation of the mitogen-activated protein kinase
(MAPK) pathway is needed for complete cellular migration
[27]. Transient dephosphorylation of FAK leads to Rho
activation, actin depolymerization, focal adhesion turnover,
and loss of cellular polarity. Phosphorylation of FAK inhibits
Rho activity, promoting stablization of focal adhesions and
activation of Rac and Cdc42, both of which are required
for fascin microspike formation and lamellipodial formation
[28,29,7], demonstrating that the Rho GTPases must work
in concert to produce a motile cell.
Contrary to these studies, it is suggested that decreased
IGF-IR levels lead to increased motility and invasiveness in
MCF-7 cells by increasing Rac and Cdc42 activity and
decreasing Rho activity and E-cadherin expression [30].
These data imply that activation of IGF-IR stabilizes the
E-cadherin–β-catenin complex and potentially activates
RhoA, promoting cellular aggregation.
Studies demonstrating the effect of IGF-I on neuroblas-
toma cell motility suggest a peripheral role for RhoA or
RhoC. These studies are based on observations made of
IGF-I-stimulated neuroglial Schwann cell motility [31]. IGF-
I stimulation of SH-SY5Y and SHEP human neuroblas-
toma cells leads to Rac1 mediated lamellipodial extension
through the PI3K and MAPK pathways [31]. Blocking SH-
SY5Y IGF-IR with αIR-3 antibody inhibits cellular motility.
Furthermore, when PTEN was expressed in SH-SY5Y
cells, motility was also inhibited. The presence of PTEN
prevents phosphorylation and activation of xxAkt by PI3K
suggesting activation of Akt is integral in neuroblastoma
motility.
A positive feedback loop of growth factor signaling has
been described in Src transformed human pancreatic
cancer cells. Activation of the PI3K pathway leads to
phosphorylation of Akt and upregulation of IGF-IR [32].
IGF-IR expression is diminished when PTEN is expressed,
indicating that Src transformation leads to an increase in
PI3K activation, phosphorylation of Akt, and upregulation
of IGF-IR. IGF-IR is activated by IGF-I, increasing the level
of PI3K activation, increasing Akt phosphorylation, sustain-
ing IGF-IR expression, and increasing cellular motility and
metastasis. Since pancreatic cancer cells have not been
shown to produce IGF-I, it is thought that the pancreatic
stroma, a hallmark of pancreatic tumors and a rich source
of IGF, is the main source of IGF in this system.
In the RIP1–Tag2 murine model of pancreatic tumorigene-
sis, IGF-IR is elevated in invasive tumors [33]. In this model,
IGF-II activates IGF-IR in hyperproliferative, oncogene-
expressing β cells and is uniformly expressed in invasive
tumors. As a consequence, overexpression of IGF-IR, acti-
vated by IGF-II in an autocrine manner, accelerates tumor
progression and enhances invasive and metastatic capabil-
ities of the cells, presumably mediated by Rac and Rho.
A comparison of two human neuroblastoma cell lines,
SH-SY5Y- and IGF-IR-transfected SHEP (SHEP/IGF-IR),
shows that the two cell lines are equally stimulated to
migrate in response to IGF-I stimulation via Rac activation
[31]. Interestingly, SHEP/IGF-IR and SH-SY5Y utilize dif-
ferent isoforms of insulin receptor substrate (IRS-1 and
IRS-2, respectively) to transduce signals from IGF-IR.
Treatment with either a PI3K inhibitor (LY294002) or a
MEK1 inhibitor (PD98059), alone or in combination,
decreases cellular motility equally in the two cell types.
Regardless of which IRS is used to transduce the signal
from IGF-IR, both PI3K and MAPK are utilized in Rac1-
mediated neuroblastoma motility.177
IGF-I treatment of the MDA-MB-231-BO breast cancer cell
line, a metastatic variant derived from an osseous metasta-
sis of MDA-MB-231 parent cells, stimulates motility in the
variant but not the parental cell lines [34]. In contrast to the
neuroblastoma studies, inhibition of ROCK with Y27632
implicates activation of RhoA and RhoC in conferring MDA-
MB-231 BO motility. IRS-2 is preferentially phosphorylated
in the metastatic variant, leading to increased activation of
the PI3K and MAPK pathways. In addition to motility, signal-
ing through IGF-IR and IRS-2 leads to an increase in
anchorage-independent growth and cell adhesion. These
data demonstrate that a variety of aspects of the breast
cancer metastatic phenotype are specifically regulated
through IRS-2. Taken together, the observations made in
MCF-7, MDA-231 BO, and neuroblastoma cells suggest
that activation of the GTPases may be dependent on the
adapter molecules that transduce the signal from IGF-IR.
To add to the complexity, both IGF-I and IGF-II can inter-
act with IGF-IR, the insulin receptor (IR), or a heterodimer
of IGF-IR/IR, thus eliciting numerous cellular responses
[35]. These responses can be further modulated by the
IGF-binding proteins (IGFBPs) and the IGFBP-related
proteins (IGFBP-rPs), which can limit binding of ligand to
receptor or elicit their own cellular signals. To date, several
IGFBPs and IGFBP-rPs have been identified and play an
active role in IGF signaling in normal and transformed
cells. Limiting access of IGF to its receptor can further
regulate activation of IGF-IR and breast cancer cell motility
by IGFBPs. This is specifically illustrated in studies
showing that IGFBP-1 reduces MDA-MB-231-BO cell
motility by limiting IGF-I effects on the cell [35].
In the same study that identified RhoC GTPase as being
expressed in IBC, another gene, LIBC/Wisp3, a bona fide
tumor suppressor gene, was cloned and identified as
being lost in a significant number of IBC tumors [3,36].
The tumor suppressor activity of LIBC/Wisp3 reduces
IBC anchorage-independent growth, invasiveness, and
angiogenic potential, and decreases tumor formation
when implanted orthotopically in nude mice [36].
LIBC/Wisp3 is a low-affinity IGFBP, or more specifically
an IGFBP-rP, denoted IGFBP-rP9. Data suggest that loss
of IGFBP-rP9 in IBC may lead to an increase in IGF sig-
naling, which potentially activates the Rho GTPases,
specifically RhoC.
Epidermal growth factor (EGF)
The EGF receptor (EGFR) and its oncogenic relative
Her2/neu are commonly expressed in breast cancer, includ-
ing up to 60% of IBC tumors [1]. EGFR overexpression is
also said to occur in as many as 90% of pancreatic tumors
[37]. EGF-induced cellular motility and invasion by the Rho
is well documented. Small breast tumors (<1 cm) with a
propensity to metastasize, particularly IBC tumors, concor-
dantly overexpress RhoC GTPase and Her2/neu [38].
In vivo invasive and metastatic properties of the MTLn3 rat
mammary carcinoma cell line are significantly diminished
when transfected with dominant negative forms of RhoA,
Rac1, and Cdc42 [39]. MTLn3 cells harboring dominant
negative forms of the GTPases are also refractory to EGF-
induced growth and invasion in vitro. Similarly, a dose-
dependent increase of RhoA-mediated in vitro cellular
invasion is seen for the Panc-1 human pancreatic cancer
cell line stimulated with EGF [40]. Treatment of the cells
with statins, inhibitors of 3-hydroxy-3-methyl-coenzyme A,
abrogates EGF-induced invasion, presumably by prevent-
ing RhoA from localizing in the inner plasma membrane,
where it can be activated by RhoGEFs [40].
EGF activation of the Rho GTPases can occur through
activation of the RhoGEFs and inactivation of the
RhoGAPs. The Vav family of RhoGEFs is an example of a
group of GEFs that are activated in response to EGF stim-
ulation of EGFR [15,18]. The Vav family consists of three
members that interact with and activate RhoA, Rac1, and
Cdc42 [15,18]. Vav1 is found primarily in hematopoietic
cells, while Vav2 and Vav3 are expressed ubiquitously in
tissues [15,18]. All three Vav proteins have been impli-
cated in breast cancer metastasis and may prove to be
very important in the aberrant activation of Rho GTPases
during the metastatic cascade.
p190 RhoGAP was first identified as a phosphorylated
protein associated with p120 RasGAP in v-src-trans-
formed, EGF stimulated cells [13,41]. EGF stimulation
induces tyrosine phosphorylation of p190 RhoGAP,
leading to heterodimer formation with p120 RasGAP and
a loss in GTP-binding, decreased GTP hydrolysis, and
actin reorganization [13]. At the time of EGF activation,
the p190 and p120 proteins are located at the inner
plasma membrane [41]. Upon heterodimer formation, the
p190/p120 complex becomes associated with EGFR in
an endocytic compartment and is internalized [41]. Rea-
sonably, during receptor recycling the GAPs are released
and can inactivate remaining GTP-bound Rho. The p190-
A isoform was first identified as a tumor suppressor gene,
thus suggesting that loss or inactivation of GAP proteins
can lead to dysregulation and subsequent activation of
Rho GTPases [19].
Conclusion
A great deal of work performed over the past five years
has given insight into mechanisms of growth-factor-
induced motility. Clearly, the Rho GTPases occupy a
central and pivotal role as a molecular switch, controlling
aspects of the cystoskeletal rearrangement during motility
and invasion. As more studies focus on the role of the Rho
GTPases in metastasis, a complex web of molecules
involved in regulating activation of the GTPases and
crosstalk between different Rho subfamily members will
be elucidated. Given the central role occupied by these
Available online http://breast-cancer-research.com/content/5/3/174178
molecules, understanding their biology is essential in
understanding a key element of the metastatic phenotype.
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